Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
VEGFA165 gene therapy ameliorates blood-labyrinth barrier breakdown and hearing loss
Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi
Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi
View: Text | PDF
Research Article Angiogenesis

VEGFA165 gene therapy ameliorates blood-labyrinth barrier breakdown and hearing loss

  • Text
  • PDF
Abstract

Millions of people are affected by hearing loss. Hearing loss is frequently caused by noise or aging and often associated with loss of pericytes. Pericytes populate the small vessels in the adult cochlea. However, their role in different types of hearing loss is largely unknown. Using an inducible and conditional pericyte depletion mouse model and noise-exposed mouse model, we show that loss of pericytes leads to marked changes in vascular structure, in turn leading to vascular degeneration and hearing loss. In vitro, using advanced tissue explants from pericyte fluorescence reporter models combined with exogenous donor pericytes, we show that pericytes, signaled by VEGF isoform A165 (VEGFA165), vigorously drive new vessel growth in both adult and neonatal mouse inner ear tissue. In vivo, the delivery of an adeno-associated virus serotype 1–mediated (AAV1–mediated) VEGFA165 viral vector to pericyte-depleted or noise-exposed animals prevented and regenerated lost pericytes, improved blood supply, and attenuated hearing loss. These studies provide the first clear-cut evidence that pericytes are critical for vascular regeneration, vascular stability, and hearing in adults. The restoration of vascular function in the damaged cochlea, including in noise-exposed animals, suggests that VEGFA165 gene therapy could be a new strategy for ameliorating vascular associated hearing disorders.

Authors

Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi

×

Figure 4

Pericyte-driven angiogenesis is controlled by VEGFA165 signaling.

Options: View larger image (or click on image) Download as PowerPoint
Pericyte-driven angiogenesis is controlled by VEGFA165 signaling.
(A) Th...
(A) The illustration shows selective blockage of VEGFA165 signaling with the drug BAW2881, which targets 2 VEGFA receptors, Flt1 and KDR/Flk1. (B) The number of new vessels is significantly reduced in a dose-dependent manner when VEGFA receptors are blocked with the specific VEGFA blocker, BAW2881 (n = 3 for control group, n = 4 for 1 nM, n = 3 for 4 nM, n = 3 for 40 nM, and ****P < 0.0001 by 1-way ANOVA). (C and D) Representative confocal projection images show branch formation in the VEGFA165 and VEGFA receptor blocked groups. (E) Illustration of construction of the AAV1-FLEX-VEGFA165-GFP viral vector, a Cre-dependent inversion gene switch (FLEX) vector, which specifically targets pericytes to produce VEGFA165. (F) Pericytes (red, genetically labeled by tdTomato) drive sprouting angiogenesis, as seen on day 5 in a Pdgfrb-CreER/tdTomato mouse cochlea. (G) The green AAV1-FLEX-VEGFA165-GFP signal is primarily targeted in tdTomato-labeled pericytes. (H) Merged image from F and G. (I and J) Sprouting growth in the AAV1-GFP control and AAV1-FLEX-VEGFA165 viral vector groups. (K) The number of branches is significantly higher in the AAV1-FLEX-VEGFA165 viral vector–transfected strial explant (n = 4 for AVV1-GFP group, n = 5 for AAV1-VEGFA165 group, and *P < 0.05 by Student’s t test). Data are presented as mean ± SEM. Scale bars: 100 μm (C, D, F–H), 150 μm (I, J).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts